Structural myelin defects are associated with low axonal ATP levels but rapid recovery from energy deprivation in a mouse model of spastic paraplegia

PLoS Biol. 2020 Nov 16;18(11):e3000943. doi: 10.1371/journal.pbio.3000943. eCollection 2020 Nov.

Abstract

In several neurodegenerative disorders, axonal pathology may originate from impaired oligodendrocyte-to-axon support of energy substrates. We previously established transgenic mice that allow measuring axonal ATP levels in electrically active optic nerves. Here, we utilize this technique to explore axonal ATP dynamics in the Plpnull/y mouse model of spastic paraplegia. Optic nerves from Plpnull/y mice exhibited lower and more variable basal axonal ATP levels and reduced compound action potential (CAP) amplitudes, providing a missing link between axonal pathology and a role of oligodendrocytes in brain energy metabolism. Surprisingly, when Plpnull/y optic nerves are challenged with transient glucose deprivation, both ATP levels and CAP decline slower, but recover faster upon reperfusion of glucose. Structurally, myelin sheaths display an increased frequency of cytosolic channels comprising glucose and monocarboxylate transporters, possibly facilitating accessibility of energy substrates to the axon. These data imply that complex metabolic alterations of the axon-myelin unit contribute to the phenotype of Plpnull/y mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials
  • Adenosine Triphosphate / metabolism*
  • Animals
  • Axons / metabolism
  • Disease Models, Animal
  • Energy Metabolism
  • Female
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mice, Transgenic
  • Microscopy, Electron, Transmission
  • Microscopy, Immunoelectron
  • Myelin Proteolipid Protein / deficiency
  • Myelin Proteolipid Protein / genetics
  • Myelin Sheath / metabolism*
  • Myelin Sheath / pathology
  • Optic Nerve / metabolism
  • Optic Nerve / pathology
  • Paraplegia / genetics
  • Paraplegia / metabolism*
  • Paraplegia / pathology
  • Phenotype

Substances

  • Myelin Proteolipid Protein
  • Plp1 protein, mouse
  • Adenosine Triphosphate

Grants and funding

This work was supported by the Deutsche Forschungsgemeinschaft (DFG, www.dfg.de: grant number Hi1414/6-1 (SPP1757) to JH; WE2720/4-1 to HBW; MO 1084/2-1 (FOR2848, P8) to WM; SFB-TR43 to KAN; Na262/1-2 (SPP1757) to KAN; Research Center Nanoscale Microscopy and Molecular Physiology of the Brain, CNMPB, to KAN and WM) as well as the European Research Council (ERC, erc.europa.eu: ERC Advanced Grants AxoGlia and MyeliNANO to KAN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.